Evolva Supports Advances in Research at Resveratrol 2018 Conference

October 18th, 2018

18 October, 2018 –  Resveratrol 2018, the 5th International Conference on Resveratrol and Health, begins today and will be held October 18-20, 2018 in Xi’an, China. This conference is the leading annual knowledge sharing event for the global resveratrol community. Evolva’s Veri-teTM resveratrol is committed to the advancement of the science behind resveratrol to bring innovative products to the market and is proud to be a sponsor of Resveratrol 2018.

Each year, the conference gathers the reigning voices in resveratrol research, all of whom have a common goal of unlocking knowledge and understanding of resveratrol’s potential in supporting health and wellness. This year’s conference is expected to draw over 100 scientists invested in resveratrol research from around the globe.

“We look forward to bringing together the resveratrol research community each year and are thrilled to see such a strong turnout of researchers and scientists at Resveratrol 2018. We are very excited to showcase the latest science and highlight this community’s commitment to understanding the various potential health benefits of resveratrol,” said Ole Vang, Associate Professor, Department of Science and Environment at Roskilde University, and a Resveratrol 2018 Conference Director.  

This year’s conference will explore an expansion of topics, such as the influence of resveratrol on the microbiome; its role in supporting skin, cardiovascular and bone health; and its antioxidant properties and therapeutic potential. Scientists from independent research groups using Veri-teTM resveratrol will present their findings during the three-day event:

  • Peter Howe, PhD, Emeritus Professor of Clinical Nutrition at the University of Newcastle, Australia will present preliminary data from the longest resveratrol clinical trial undertaken in postmenopausal women.
  • Scott Boyer, founder and scientific advisor at Nutrinovate AB, Sweden will present data showcasing the bioavailability of resveratrol when delivered via the lining of the mouth.
  • Karen Brown, PhD, Professor of Translational Cancer Research at the University of Leicester, UK will discuss the potential role of resveratrol in the treatment of colorectal cancer.

At Evolva, we are committed to supporting clinical trials and research innovations that help our partners reimagine the potential health benefits of resveratrol,” said Sally Aaron, SVP Health Ingredients and Marketing at Evolva. “Resveratrol 2018 is such an important conference for us to support because it highlights the wealth of new research on resveratrol across a number of new benefits areas, like bone health. The versatility of resveratrol continues to be supported by a strong scientific foundation.”

For more information, visit www.veriteresveratrol.com.


About Evolva
Evolva solves the supply chain issues of nature through a 21st century mix of biotechnology and fermentation. We develop, make and sell ingredients that provide significant health, wellness and nutrition benefits to people in their daily life, but whose supply chain issues have limited their use until now. Our flagship ingredients are stevia, nootkatone and resveratrol. To make our world sustainable requires nature and technology to work together as one, and our aim is to play a (small) part in achieving this transformation. For more information see www.evolva.com